Evidence map›Paper›PMID 41247443›Full record

Trial reportJournal of assisted reproduction and genetics2026

Intrauterine platelet-rich plasma infusion for recurrent implantation failure: a pilot randomized controlled single-blinded clinical trial in the USA.

Lusine Aghajanova, Michael Strug, Jiaqi Zhang, Ruth B Lathi

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of assisted reproduction and genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03379649 (Platelet Rich Plasma for Patients With Recurrent Implantation Failure), which is not on this map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03379649 early_phase1completednot on this map

Platelet Rich Plasma for Patients With Recurrent Implantation Failure: A Prospective Randomized Pilot Study

TypeinterventionalSponsorStanford UniversityRan2019 to 2023Enrolled50ConditionsInfertilityArmsPlatelet rich plasma, Placebo
3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Lusine AghajanovaDivision of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Stanford University School of Medicine, 1195 West Fremont Avenue, Sunnyvale, CA, 94087, USA. aghajano@stanford.edu.ORCID http://orcid.org/0000-0002-3515-9252
Michael StrugDivision of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Stanford University School of Medicine, 1195 West Fremont Avenue, Sunnyvale, CA, 94087, USA.
Jiaqi ZhangDepartment of Obstetrics and Gynecology, Stanford University School of Medicine, Palo Alto, CA, USA.
Ruth B LathiDivision of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Stanford University School of Medicine, 1195 West Fremont Avenue, Sunnyvale, CA, 94087, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo evaluate the feasibility and potential therapeutic effect of intrauterine platelet-rich plasma (PRP) infusion in patients with recurrent implantation failure (RIF) undergoing frozen embryo transfer (FET); to characterize PRP cytokine/growth factor profiles by cycle phase and pregnancy outcomes.

methodsIn this single-blinded, pilot randomized controlled trial, 52 women with unexplained RIF, normal uterine cavity, and endometrial thickness > 7 mm were enrolled. Eleven did not complete the FET cycle, leaving 33 patients in the intention-to-treat analysis (PRP: n = 13; control: n = 20). Eight additional patients received PRP in a subsequent cycle. Participants were randomized to intrauterine PRP or saline infusion in the follicular phase (cycle day 9-12 or days 10-14 of estradiol) and luteal phase (2 days before FET). PRP was isolated from autologous peripheral blood, and 1 mL was infused. Standard treatments were continued. PRP cytokine profiling was performed via Luminex analysis. PRIMARY OUTCOME: pregnancy rate (PR). Secondary: clinical PR, miscarriage rate (MR), live birth rate (LBR), and cytokine correlations.

resultsBaseline and embryo-related variables were similar between groups. In the intention-to-treat analysis, PR was 69% in the PRP group vs 50% in controls (p = 0.27); LBR was 46% vs 25% (p = 0.27); MR was 22% vs 50% (p = 0.35). PRP was well tolerated. Eight cytokines differed by cycle phase. Lower luteal levels of CCL1, CCL26, and IL-23 correlated with live birth; higher CCL1 and CCL26 correlated with miscarriage.

conclusionWhile not statistically significant, PRP showed trends toward improved outcomes in RIF and was safe. Cytokine profiles varied by cycle phase and may reflect markers of fertility or treatment response.

trial registrationThe study was prospectively registered in the ClinicalTrials.gov Protocol Registration System (NCT03379649, https://clinicaltrials.gov/search?locStr=Sunnyvale,%20CA&country=United%20States&state=California&city=Sunnyvale&cond=Recurrent%20Implantation%20Failure&intr=Platelet%20Rich%20Plasma ). The study was activated on 01/16/2019 and closed on 12/20/2023. The first patient was enrolled on 1/20/2019 and last patient was enrolled on 1/25/2023.

Indexed as

Embryo ImplantationEmbryo TransferPlatelet-Rich PlasmaAdultBirth RateCytokinesFemaleFertilization in VitroHumansLive BirthPilot ProjectsPregnancyPregnancy OutcomePregnancy RateSingle-Blind MethodUnited StatesCytokinesClinical trialEndometriumFrozen Embryo transferPlatelet-rich plasmaRecurrent implantation failure

Identifiers

PMID41247443
PMCPMC12901806

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.